The Journal of Clinical and Aesthetic Dermatology

Epizode

• Fabrizio Galimberti, MD, PhD: The Importance of Targeted Therapy for GPP Treatment 01.07.2026 7min

  Send us Fan Mail Fabrizio Galimberti, MD, PhD, reviews the molecular biology behind spesolimab for the treatment of generalized pustular psoriasis (GPP). He highlights the distinction between psoriasis and GPP, while discussing the role that the interleukin-36 pathway plays in inflammation. Dr. Galimberti emphasizes the importance of targeted treatment for flare reduction and improved outcomes in GPP management.
• James Del Rosso, DO: JCAD June 2026 Issue Highlights 29.06.2026 13min

  Send us Fan Mail James Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the June 2026 issue of JCAD.
• Tina Bhutani, MD, MAS, FAAD: Use of Spesolimab for Generalized Pustular Psoriasis 04.06.2026 6min

  Send us Fan Mail Tina Bhutani, MD, MAS, FAAD, discusses the use of spesolimab, an interleukin-36 receptor blocker, for the treatment of patients with generalized pustular psoriasis. Drawing on real-world patient cases, she highlights its role in rapidly controlling acute flares, improving patient quality of life, and reducing reliance on therapies originally developed for plaque psoriasis.
• James Del Rosso, DO: JCAD May 2026 Issue Highlights 29.05.2026 20min

  Send us Fan Mail James Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the May 2026 issue of JCAD.
• Bruce Strober, MD, PhD, FAAD: Providing Care With Risankizumab in Psoriasis 15.05.2026 7min

  Send us Fan Mail Bruce Strober, MD, PhD, FAAD, a clinical professor of dermatology at Yale University, discusses his extensive experience in treating patients with psoriasis. He describes his experience treating these patients with risankizumab (Skyrizi), highlighting its efficacy in treating chronic plaque psoriasis and its effectiveness for patients with comorbidities. The therapy has shown rapid improvement in high-impact areas of the body such as the scalp, palms, and soles. Dr. Strober e...
• James Del Rosso, DO: JCAD April 2026 Issue Highlights 30.04.2026 22min

  Send us Fan Mail James Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the April 2026 issue of JCAD.
• James Del Rosso, DO, and Joseph Merola, MD, MMSc: What’s New in Cutaneous Lupus Erythematosus 28.04.2026 27min

  Send us Fan Mail James Del Rosso, DO, and Joseph Merola, MD, MMSc, discuss recent advances in the treatment of cutaneous lupus erythematosus (CLE). They emphasize the importance of early detection and appropriate laboratory testing to differentiate between cutaneous-only disease and systemic lupus. They highlight the late-breaking phase 2/3 AMETHYST trial (NCT05531565) data for litifilimab, which showed a significant reduction in skin disease activity in patients with CLE by Week 16.
• James Del Rosso, DO, Diego Dasilva, MD, and Graham Litchman, DO, MS: Management of Severe Nail Psoriasis and Early Psoriatic Arthritis 24.04.2026 18min

  Send us Fan Mail James Del Rosso, DO, Diego Ruiz Dasilva, MD, and Graham Litchman, DO, MS, discuss the clinical efficacy of bimekizumab (Bimzelx) for patients with severe fingernail psoriasis and concomitant psoriatic arthritis (PsA). They highlighted a case of a 56-year-old woman with extensive dystrophic changes across all 10 fingernails and PsA who had been misdiagnosed and treated for years with antifungals and antibiotics without improvement. After initiating bimekizumab, she achieved c...
• James Del Rosso, DO, and David Cotter, MD, PhD: Clinical Management of Conjunctivitis, Erythema, and Arthralgia in AD 01.04.2026 25min

  Send us Fan Mail James Del Rosso, DO, and David Cotter, MD, PhD, discuss the clinical safety and efficacy of nemolizumab for patients with atopic dermatitis (AD). They highlighted a case of an 11-year-old female patient with severe AD who switched from dupilumab (Dupixent) to nemolizumab (Nemluvio). The patient achieved rapid itch reduction and resolution of conjunctivitis and facial erythema. In another case, a 22-year-old female patient with long-standing AD and joint pain switched to nemol...
• James Del Rosso, DO: JCAD March 2026 Issue Highlights 30.03.2026 18min

  Send us Fan Mail James Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the March 2026 issue of JCAD.
• Ted Lain, MD, MBA: Long-Term Results of Deuruxolitinib for Alopecia Areata 17.03.2026 7min

  Send us Fan Mail Ted Lain, MD, a board-certified dermatologist at Sanova Dermatology in Austin, Texas, shares his extensive experience with deuruxolitinib (Leqselvi) for the treatment of patients with moderate-to-severe alopecia areata. Drawing on 5 years of long-term extension data, Dr. Lain explains that patients generally maintained hair regrowth they achieved early in treatment, with no loss of effect over time. He emphasizes that this durability is crucial, as patients are often most afr...
• James Del Rosso, DO: JCAD February 2026 Issue Highlights 26.02.2026 24min

  Send us Fan Mail James Del Rosso, DO, the Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the February 2026 issue of JCAD.
• James Del Rosso, DO, and David Cotter, MD, PhD: The Use of Gene-Expression Profile Testing for Effective Atopic Dermatitis Treatment 19.02.2026 19min

  Send us Fan Mail James Del Rosso, DO, and David Cotter, MD, PhD, discuss using gene expression profile testing, such as the AdvanceAD-Tx test, to provide effective treatment for patients with atopic dermatitis. AdvanceAD-Tx allows clinicians to match therapy based on patients’ immune profiles using molecular testing. Drs. Del Rosso and Cotter also review the benefits of using the test not only at baseline, but also throughout treatment in order to tailor their atopic dermatitis therapy and av...
• Amy McMichael, MD: Eight-Week Outcomes With Deuruxolitinib in Alopecia Areata 19.02.2026 6min

  Send us Fan Mail Amy McMichael, MD, a clinical professor and chair of the Department of Dermatology at Wake Forest School of Medicine, discusses deuruxolitinib for patients with alopecia areata. She highlights its 8-week efficacy compared to placebo in clinical trials. The medication provided significant improvement in hair regrowth at the 8-mg dose, with minimal adverse events. She emphasized the need to perform standard baseline and intermittent lab tests in patients, similar to other Janus...
• Graham Litchman, DO, MS: Understanding Long-Term Treatment Success in a Patient With Psoriasis 17.02.2026 8min

  Send us Fan Mail Graham Litchman, DO, MS, a board-certified dermatologist at Vivida Dermatology in Las Vegas, Nevada, discusses a patient case involving a 54-year-old female patient with psoriasis who did not respond well to conventional treatments or systemic steroids. Dr. Lichtman introduced her to risankizumab (Skyrizi), explaining its mechanism of action, adverse events, and dosing schedule. The patient experienced significant improvement by the 3-month mark, with most plaques disappearin...
• James Del Rosso, DO: JCAD January 2026 Issue Highlights 30.01.2026 22min

  Send us Fan Mail James Del Rosso, DO, the Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the January 2026 issue of JCAD.
• Aaron Farberg, MD: Real-World Experiences in Alopecia Areata Treatment 22.01.2026 5min

  Send us Fan Mail Dr. Aaron Farberg, a board-certified dermatologist and founder of Bear Dermatology in Dallas, Texas, discusses the evolving treatment landscape for alopecia areata with a focus on Janus kinase inhibitors and how he has used this type of treatment in his practice.
• Arash Mostaghimi, MD, MPH, FAAD: Considerations for the Use of Deuruxolitinib in Patients with Alopecia Areata 02.12.2025 4min

  Send us Fan Mail Dr. Mostaghimi discusses the speed and depth of efficacy of deuruxolitinib for providing hair regrowth in patients with severe alopecia areata.
• James Del Rosso, DO: JCAD November 2025 Issue Highlights 20.11.2025 20min

  Send us Fan Mail Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the November 2025 issue of JCAD.
• Extended-cut Podcast—James Del Rosso, DO, and David G. Cotter, MD, PhD: Targeting the IL-31 Neuroimmune Pathway for Treating Prurigo Nodularis 13.11.2025 21min

  Send us Fan Mail Drs. Del Rosso and Cotter discuss advances in the molecular understanding of prurigo nodularis, which have enabled the development of targeted pharmaceuticals that treat the root of this condition.